Rapport Therapeutics (RAPP) Competitors $12.68 -0.32 (-2.46%) Closing price 04:00 PM EasternExtended Trading$12.68 0.00 (0.00%) As of 04:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends RAPP vs. PTGX, MESO, CNTA, BHC, HRMY, CGON, TARS, JANX, AGIO, and NAMSShould you be buying Rapport Therapeutics stock or one of its competitors? The main competitors of Rapport Therapeutics include Protagonist Therapeutics (PTGX), Mesoblast (MESO), Centessa Pharmaceuticals (CNTA), Bausch Health Companies (BHC), Harmony Biosciences (HRMY), CG Oncology (CGON), Tarsus Pharmaceuticals (TARS), Janux Therapeutics (JANX), Agios Pharmaceuticals (AGIO), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. Rapport Therapeutics vs. Protagonist Therapeutics Mesoblast Centessa Pharmaceuticals Bausch Health Companies Harmony Biosciences CG Oncology Tarsus Pharmaceuticals Janux Therapeutics Agios Pharmaceuticals NewAmsterdam Pharma Protagonist Therapeutics (NASDAQ:PTGX) and Rapport Therapeutics (NASDAQ:RAPP) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability, community ranking and analyst recommendations. Does the MarketBeat Community prefer PTGX or RAPP? Protagonist Therapeutics received 279 more outperform votes than Rapport Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Rapport Therapeutics an outperform vote while only 61.09% of users gave Protagonist Therapeutics an outperform vote. CompanyUnderperformOutperformProtagonist TherapeuticsOutperform Votes28161.09% Underperform Votes17938.91% Rapport TherapeuticsOutperform Votes2100.00% Underperform VotesNo Votes Is PTGX or RAPP more profitable? Protagonist Therapeutics has a net margin of 52.76% compared to Rapport Therapeutics' net margin of 0.00%. Protagonist Therapeutics' return on equity of 34.68% beat Rapport Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protagonist Therapeutics52.76% 34.68% 30.98% Rapport Therapeutics N/A N/A N/A Does the media favor PTGX or RAPP? In the previous week, Protagonist Therapeutics had 8 more articles in the media than Rapport Therapeutics. MarketBeat recorded 10 mentions for Protagonist Therapeutics and 2 mentions for Rapport Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.51 beat Rapport Therapeutics' score of 0.34 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rapport Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate PTGX or RAPP? Protagonist Therapeutics currently has a consensus target price of $56.00, indicating a potential upside of 44.52%. Rapport Therapeutics has a consensus target price of $35.00, indicating a potential upside of 176.03%. Given Rapport Therapeutics' higher probable upside, analysts clearly believe Rapport Therapeutics is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Rapport Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of PTGX or RAPP? 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 5.4% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, PTGX or RAPP? Rapport Therapeutics has lower revenue, but higher earnings than Protagonist Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtagonist Therapeutics$60M38.49-$78.96M$2.6614.57Rapport TherapeuticsN/AN/A-$34.79MN/AN/A SummaryProtagonist Therapeutics beats Rapport Therapeutics on 11 of the 14 factors compared between the two stocks. Get Rapport Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPP vs. The Competition Export to ExcelMetricRapport TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$463.78M$7.04B$5.77B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E RatioN/A6.1326.4618.82Price / SalesN/A312.72448.1776.45Price / CashN/A67.8344.0437.47Price / BookN/A6.747.634.64Net Income-$34.79M$138.11M$3.18B$245.69M7 Day Performance-20.25%-2.02%-1.82%-2.63%1 Month Performance-4.45%-1.54%0.22%-2.37%1 Year PerformanceN/A-3.14%17.49%13.65% Rapport Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPPRapport Therapeutics1.6498 of 5 stars$12.68-2.5%$35.00+176.0%N/A$463.78MN/A0.00N/APTGXProtagonist Therapeutics3.7143 of 5 stars$38.670.0%$56.00+44.8%+41.4%$2.30B$60M14.54120Earnings ReportInsider TradeNews CoverageGap UpMESOMesoblast0.8266 of 5 stars$17.90-2.9%$18.00+0.6%+757.2%$2.27B$5.90M0.0080Upcoming EarningsCNTACentessa Pharmaceuticals3.461 of 5 stars$17.07-3.1%$25.83+51.3%+57.1%$2.25B$6.85M-11.16200Insider TradeHigh Trading VolumeBHCBausch Health Companies3.8517 of 5 stars$6.15-3.6%$7.42+20.6%-16.5%$2.22B$8.76B-12.8220,270Earnings ReportNews CoverageHRMYHarmony Biosciences4.724 of 5 stars$38.98-0.3%$55.00+41.1%+5.7%$2.22B$582.02M18.47200Analyst ForecastAnalyst RevisionNews CoverageCGONCG Oncology1.8516 of 5 stars$28.52+0.1%$63.88+124.0%-36.4%$2.17B$200,000.000.0061News CoverageTARSTarsus Pharmaceuticals1.4327 of 5 stars$50.22-3.8%$56.00+11.5%+60.2%$1.92B$17.45M-13.1850JANXJanux Therapeutics3.1281 of 5 stars$36.37-2.2%$89.90+147.2%+273.2%$1.91B$13.05M-31.0930AGIOAgios Pharmaceuticals4.3459 of 5 stars$33.22-0.2%$56.33+69.6%+24.5%$1.89B$26.82M2.92390Earnings ReportShort Interest ↓NAMSNewAmsterdam Pharma3.308 of 5 stars$19.91+2.6%$41.60+108.9%-10.0%$1.84B$14.09M0.004Upcoming Earnings Related Companies and Tools Related Companies PTGX Competitors MESO Competitors CNTA Competitors BHC Competitors HRMY Competitors CGON Competitors TARS Competitors JANX Competitors AGIO Competitors NAMS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RAPP) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RAPP Stock Alerts